TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19917523
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) and Vitamin C and E (VCE) supplementation
Study: 19917523
Drug: No HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: No HRT treatment (Control)
Study: 25735993
Drug: MDMA (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (1.0 mg/kg)
Study: 15975736
Drug: mCPP (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: mCPP (0.75 mg/kg)
Study: 15285969
Drug: Seeking Safety
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seeking Safety therapy
Study: 8204997
Drug: Paroxetine 30
Normalized name: PARoxetine 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 30 mg per day
Study: 18721703
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution (control)
Study: 30707225
Drug: Repeated antenatal
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated antenatal betamethasone treatment
Study: 22469291
Drug: Up front
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up front surgery of the breast tumor followed by systemic therapy
Study: 22469291
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy followed by delayed local treatment of the breast tumor if clinically indicated
Study: 20413364
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg plus fenofibric acid 135 mg daily for 18 months
Study: 17507311
Drug: Enediyne compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enediyne compounds
Study: 15610940
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) isradipine 30 mg
Study: 15008726
Drug: ProstaLund Feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProstaLund Feedback Treatment (PLFT)
Study: 10202826
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination regimen (NVP + ddl + ZDV)
Study: 20083352
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injection
Study: 26983925
Drug: Lidocaine cream
Normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine cream
Study: 3243094
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 1.5 g and 1.2 g
Study: 3243094
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 2 g (single dose)
Study: 3243094
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 2 g for 10 days
Study: 3243094
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 1 g
Study: 3243094
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 2 g
Study: 27330698
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg bid for 3 weeks
Study: 25907848
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - wait-list IRD (no treatment)
Study: 25907848
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - typically developing readers (no treatment)
Study: 10806602
Drug: Sibrafiban with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibrafiban with ASA and heparin
Study: 30836981
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of renin-angiotensin system inhibitors (RASi) 48 hours before surgery
Study: 29369904
Drug: PRP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP treatment (1.0 × 10 platelets/cm sprayed on wound)
Study: 17608755
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg/day) for 36 months
Study: 7978420
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg droperidol (Group 1, n = 10)
Study: 7978420
Drug: 0.175 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.175 mg/kg droperidol (Group 2, n = 10)
Study: 1708060
Drug: Cilazapril 2.5
Normalized name: cilazapril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 2.5 mg
Study: 668773
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg
Study: 30580672
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy and treadmill training
Study: 26095747
Drug: Ropivacaine 0.197%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.197% with adjunct dexmedetomidine 0.3 μg·kg(‐1) (Group LAD)
Study: 19446149
Drug: Eltrombopag 50
Normalized name: eltrombopag 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 50 mg with high-fat, high-calcium breakfast
Study: 19446149
Drug: Eltrombopag 75
Normalized name: eltrombopag 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 75 mg with low-fat, low-calcium meal
Study: 19446149
Drug: Eltrombopag 75
Normalized name: eltrombopag 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 75 mg with high-fat, low-calcium meal
Study: 19446149
Drug: Eltrombopag 75
Normalized name: eltrombopag 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 75 mg with antacid containing aluminum hydroxide and magnesium carbonate
Study: 15247109
Drug: epidural ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: epidural ketamine 1 mg kg(‐1) in 10 ml plus i.m. normal saline
Study: 15247109
Drug: epidural normal
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epidural normal saline 10 ml plus i.m. normal saline 10 ml
Study: 30810382
Drug: Weekly 50
Normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly 50 mg of transdermal testosterone plus daily oral 1 mg estradiol valerate for 8 weeks
Study: 9248985
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg/kg)
Study: 27573564
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg bid)
Study: 15237706
Drug: Insulin gene
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin gene pattern risk scores (summed risk score from two single nucleotide polymorphisms: -23 Hph I; +1127 Pst I)
Study: 11904741
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of parenteral iron
Study: 11904741
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of parenteral iron
Study: 2744068
Drug: Witepsol H12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Witepsol H12 suppositories containing 75 mg, 100 mg, and 150 mg of meptazinol
Study: 2744068
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral tablet of meptazinol
Study: 76752
Drug: Acid-phosphatase reaction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-phosphatase reaction in null-A.L.L.
Study: 22906516
Drug: Disulfiram (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (250 mg/day, n = 34)
Study: 22906516
Drug: Disulfiram (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (250 mg/day) in normal DβH level genotype
Study: 22906516
Drug: Disulfiram (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (250 mg/day) in low DβH level genotype
Study: 21266648
Drug: Home use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home use of a smartphone recommending insulin doses with quarterly visits (G2)
Study: 19856688
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.25% bupivacaine (2 mL/h) plus intravenous analgesics
Study: 8721527
Drug: Acute allergen
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute allergen challenge (increasing doses every 15 min until symptoms occurred) in 9 patients.
Study: 8721527
Drug: Repeated low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Repeated low-dose allergen exposure (one small dose daily for 7 days) in 10 patients.
Study: 28132705
Drug: Substance abuse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance abuse treatment
Study: 9727214
Drug: Assertive Community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive Community Treatment (ACT) model
Study: 15953302
Drug: Relaxation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation treatment
Study: 8360369
Drug: Relaxation+efficacy-enhancement treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation+efficacy-enhancement treatment
Study: 2242740
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation
Study: 3963319
Drug: Oral premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral premedication
Study: 16030279
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg IV)
Study: 14622076
Drug: Experiential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiential treatment for depression (16-20 sessions)
Study: 8964866
Drug: rhGH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH therapy (4 IU/m2.day, sc)
Study: 1804652
Drug: Intranasal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) administration of midazolam 0.2 mg.kg‐1
Study: 1804652
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of midazolam 0.2 mg.kg‐1
Study: 1763589
Drug: Buprenorphine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.15 mg)
Study: 6402201
Drug: Meptazinol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol (50 mg)
Study: 8368552
Drug: Morphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (5 mg)
Study: 6402201
Drug: Pethidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (50 mg)
Study: 6402201
Drug: Intramuscular analgesic
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular analgesic system
Study: 6402201
Drug: Intravenous on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous on demand systems
Study: 12215236
Drug: Nicotine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (7 mg/24 h)
Study: 24777591
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose of NOMAC/E2 (2.5/1.5 mg)
Study: 16968566
Drug: Eszopiclone 2
Normalized name: eszopiclone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eszopiclone 2 mg
Study: 16477959
Drug: Eszopiclone 1
Normalized name: eszopiclone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eszopiclone 1 mg
Study: 10924966
Drug: Hyperfractionation at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionation at 1.2 Gy/fraction, twice daily, 5 days/week to 81.6 Gy/68 fractions/7 weeks
Study: 10924966
Drug: Accelerated fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated fractionation with concomitant boost at 1.8 Gy/fraction/day, 5 days/week and 1.5 Gy/fraction/day to a boost field for the last 12 treatment days to 72 Gy/42 fractions/6 weeks
Study: 30501824
Drug: No steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroid cover (group 2)
Study: 26581718
Drug: DEX implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX implant 0.7 mg
Study: 26581718
Drug: DEX implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX implant 0.35 mg
Study: 23072538
Drug: Sugar solution
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar solution (control)
Study: 12421773
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose corticosteroid infusion for 48 hours after head injury
Study: 12198662
Drug: Sandostatin LAR
Normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sandostatin LAR 30 mg injection once every 4 weeks for 6 doses
Study: 9518395
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (3 or more insulin injections daily or continuous subcutaneous infusion of insulin, guided by 4 or more glucose tests per day)
Study: 9518395
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (1 or 2 insulin injections daily)
Study: 7536209
Drug: rhIGF‐I (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I (120 micrograms/kg, sc, daily)
Study: 214218
Drug: oral 5‐Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral 5‐Fluorouracil (5FU)
Study: 7043345
Drug: Ticarcillin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin (6 g intravenously immediately after delivery, with a second 3-g dose 6 to 8 hours after delivery for some patients)
Study: 24626789
Drug: Pharmacotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy and family‐focused treatment (21 sessions over 9 months)
Study: 24626789
Drug: Pharmacotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy and enhanced care (three weekly sessions of family psychoeducation)
Study: 10531630
Drug: Methadone formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone formulation 2
Study: 10531630
Drug: Methadone formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone formulation 3
Study: 10531630
Drug: Methadone formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone formulations (all)
Study: 24463982
Drug: Placebo Oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Appliance (POA)
Study: 10740301
Drug: Intravenous ethamsylate
Normalized name: ethamsylate
DrugBank: Etamsylate (DB13483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ethamsylate (12.5 mg/kg) six hourly for four days
Study: 7039401
Drug: FPL 57787
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPL 57787 18 mg x 4
Study: 20136418
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of 2.5 mg (0.1 ml) bevacizumab
Study: 10340796
Drug: Methylprednisolone pulse
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulse treatment
Study: 8636344
Drug: GH administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH administration (0.1 IU/kg x day)
Study: 8636344
Drug: T3 administration
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T3 administration (40 microg on even dates, 20 microg on uneven dates)
Study: 1767711
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of H2 receptor antagonists or sucralfate (4 gr/day)
Study: 1767711
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg, single dose
Study: 53555
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg orally
Study: 17083009
Drug: MenPS (meningococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenPS (meningococcal AC plain polysaccharide vaccine)
Study: 9125680
Drug: Acetylcholine (0.15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine (0.15, 0.45, 1.5, 4.5, and 15 microg/100 ml forearm tissue/min)
Study: 7648143
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg for 1 week after operation (group 1)
Study: 2744313
Drug: Gallopamil 25
Normalized name: gallopamil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 25 mg tid
Study: 8355859
Drug: Gallopamil 50
Normalized name: gallopamil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 50 mg tid
Study: 25278342
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control group (trial-matched cognitive task)
Study: 23298651
Drug: Varenicline (1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1mg twice per day)
Study: 12971556
Drug: DNP (dihydroartemisinin-napthoquine-trimethoprim),
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNP (dihydroartemisinin-napthoquine-trimethoprim), one tablet twice a day for one day
Study: 6142218
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific treatment (Control)
Study: 1297643
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg granular ibuprofen
Study: 6395810
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily sustained release theophylline
Study: 31783739
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil supplement
Study: 18263802
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) infusion (50 mg/kg body mass)
Study: 17466725
Drug: Medications and
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications and cryobrace alone (Control group)
Study: 2388876
Drug: Home therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home therapeutic drug-monitoring (TDM) method for theophylline blood levels
Study: 31566937
Drug: Cabazitaxel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (25 mg/m² IV every 3 weeks, plus prednisone daily and granulocyte colony-stimulating factor)
Study: 31566937
Drug: Androgen-signaling-targeted inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen-signaling-targeted inhibitor (1000 mg of abiraterone plus prednisone daily or 160 mg of enzalutamide daily)
Study: 31566937
Drug: Androgen-signaling-targeted inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen-signaling-targeted inhibitor
Study: 27847247
Drug: Water administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water administered throughout CRT (group C)
Study: 19216850
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) therapy for clearing heat and resolving phlegm combined with routine Western medicine.
Study: 19216850
Drug: Routine Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Western medicine only (control group).
Study: 3105748
Drug: Thyroxine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine (150 micrograms daily)
Study: 27607036
Drug: 2% Potentilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Potentilla officinalis (PO) cream
Study: 27607036
Drug: 1% hydrocortisone
Normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1% hydrocortisone acetate cream
Study: 18721243
Drug: Dexamethasone 21‐P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 21‐P (Dex 21‐P) encapsulated into erythrocytes (DEE), 9.9 +/- 4.1 mg per infusion, two infusions 14 days apart (group A)
Study: 18721243
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (0.5 mg/kg for 14 days followed by a 6 mg/weekly tapering, group B)
Study: 18721243
Drug: Sham infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham infusions (group C)
Study: 10343133
Drug: La1 supernatant
Approvals — FDA: no, EMA: no, PMDA: no
Description: La1 supernatant with omeprazole 20 mg four times a day
Study: 7438683
Drug: Ethanol 0.7
Normalized name: ethanol 0.7 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.7 gm/kg orally over 15 min followed by diazepam 10 mg intravenously over 20 min and ethanol 0.15 gm/kg/hr for 8 hr
Study: 7438683
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg intravenously over 20 min
Study: 10458050
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kg)
Study: 11331168
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine with fentanyl (2 micro g.ml(‐1))
Study: 11331168
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine with sufentanil (0.25 micro g.ml(‐1))
Study: 20693884
Drug: Fentanyl-acetaminophen group
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl-acetaminophen group
Study: 18997143
Drug: Odds ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odds ratio for African Americans not filling prescriptions
Study: 1612904
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 10(6) IU rIFN‐beta per injection